



# CIGNA MEDICAL COVERAGE POLICY

The following Coverage Policy applies to all health benefit plans administered by CIGNA Companies including plans formerly administered by Great-West Healthcare, which is now a part of CIGNA

Effective Date ..... 11/15/2010  
Next Review Date ..... 11/15/2012  
Coverage Policy Number ..... 0221

## Subject Vision Therapy/Orthoptics

### Table of Contents

Coverage Policy .....	1
General Background .....	1
Coding/Billing Information .....	5
References .....	5
Policy History .....	7

### Hyperlink to Related Coverage Policies

- Attention-Deficit/Hyperactivity Disorder (ADHD): Assessment and Treatment
- OnabotulinumtoxinA (Botox® A)
- Strabismus Correction, Surgical
- Visual Perceptual Training

### INSTRUCTIONS FOR USE

Coverage Policies are intended to provide guidance in interpreting certain **standard** CIGNA HealthCare benefit plans. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement (GSA), Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document **always supercedes** the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations. Proprietary information of CIGNA. Copyright ©2011 CIGNA

## Coverage Policy

Eye exercises are specifically excluded under many benefit plans. In addition, many benefit plans specifically exclude behavioral training and services, training, educational therapy or other nonmedical ancillary services for learning disabilities, developmental delays, autism or mental retardation. Thus, vision therapy and orthoptics are excluded under many benefit plans.

**CIGNA does not cover vision therapy or orthoptics, because they are considered experimental, investigational or unproven for the management of visual disorders and learning disabilities.**

## General Background

Vision therapy is a proposed optometric treatment method for developing efficient visual skills and processing. It has been proposed as a treatment for accommodative disorders, amblyopia, binocular disorders (strabismic and nonstrabismic), learning disabilities and ocular motility disorders. Vision therapy involves a sequence of activities individually prescribed and monitored by an optometrist or ophthalmologist with the therapeutic goal of correcting or improving specific dysfunctions of the visual system (American Academy of Ophthalmology [AAO], American Optometric Association [AOA], 1999). The AAO distinguishes between two categories of vision therapy: orthoptic and behavioral.

Orthoptics is a system of eye exercises intended to improve eye movement and visual tracking. The exercises are used not only to strengthen eye muscles, but also to improve the coordination, efficiency and functioning of

the visual system. Classic orthoptic techniques are used to correct accommodative (i.e., focusing) and convergence dysfunctions, as well as heterophorias (i.e., latent misaligned eyes) and refractive errors that might be responsible for eye fatigue and discomfort that are often aggravated by close work. Eye exercises, also referred to as orthoptics or pleoptics, have been proposed to aid specific vision problems, such as poor eye coordination, amblyopia, crossed eyes, misalignment of eyes (i.e., double vision), and inability to focus both eyes within the normal reading range. In general, ophthalmologists more narrowly define orthoptics as eye exercises provided by an orthoptist under the supervision of an ophthalmologist. The optometric definition is broader and is usually synonymous with vision therapy.

In the second category, often referred to as behavioral vision therapy, eye movement and eye-hand coordination training techniques are intended to improve visual processing skills, learning efficiency and visual-motor integration (AAO, 2007).

Modalities used in vision therapy include orthoptics or eye exercises, occlusion (i.e., eye patching) therapy, and behavioral training, as well as prescriptive or prismatic lenses, filters, computer-based training, and other materials and equipment. Colored lenses or overlays are sometimes used as part of a vision therapy program to alter contrast. A program of vision therapy involves multiple visits and practice at home over a period of several weeks to several months (AAO, AOA, 1999). A typical program may involve 24–32 visits over the course of several months, with instructions for a follow-up program to continue at home.

### **Visual Disorders**

**Accommodative Disorders:** Accommodation is the eye's ability to adjust its focus by the action of the ciliary muscle, which controls the curvature of the lens. Proper functioning of this accommodative skill allows the eye to focus and refocus quickly and effortlessly. Accommodative disorders include accommodative spasm or excess, accommodative infacility, accommodative insufficiency and ill-sustained accommodation.

**Literature Review:** There is insufficient evidence in the published, peer-reviewed, scientific literature to support the use of vision therapy in the treatment of accommodative disorders. In general, studies have been of poor design quality, with limitations that included retrospective design, lack of controls, patient selection bias, and small participant numbers.

**Amblyopia:** Amblyopia, or poorly developed vision in one eye, is one of the most common conditions treated by vision therapy techniques. Causes of amblyopia include strabismus, unequal focus which is correctable with glasses, and cloudiness in normally clear eye tissue (e.g., cataracts). The aim of treatment is to encourage use of the weak eye. Patching the dominant eye (i.e., occlusion therapy) is considered standard of care for amblyopia. Another technique used to strengthen the affected eye is the instillation of atropine sulfate drops to blur the dominant eye. The optimal time to correct amblyopia is during early childhood.

**Literature Review:** Evidence in the scientific, peer-reviewed literature indicates that occlusion therapy is safe and effective for the treatment of amblyopia. Shotton and Elliot (2008) conducted a Cochrane review (n=2 RCTs) of the evidence on interventions for strabismic amblyopia. The review included participants of any age diagnosed with strabismic amblyopia. The PEDIG (2005) study (n=64) found that supplementing occlusion therapy with near activities may produce a better visual outcome compared to non-near activities after four weeks of treatment. The RCT (n=180) by PEDIG (2006) reported that conventional part-time occlusion with any necessary glasses, was more beneficial than glasses alone for strabismic amblyopia.

An RCT (n=419) by PEDIG 2002 found both atropine and occlusion therapy for the treatment of moderate amblyopia produced improvement of similar magnitude.

Evidence supporting other vision therapy techniques as treatments for amblyopia has generally been of poor quality, with significant methodological flaws in the studies. Although several studies have been conducted, they used a wide variety of vision therapy interventions and approaches, making it difficult to compare outcomes across studies. Much of the evidence is in the form of case studies and small case series, often with patients who have failed occlusion therapy, a passive treatment. Because of the lack of well-designed and well-implemented studies, with the exception of eye patching, insufficient evidence exists in the published, peer-reviewed literature to support the use of vision therapy modalities for the treatment of amblyopia.

**Professional Societies/Organizations:** According to the AAO Preferred Practice Pattern for the management of amblyopia, occlusion therapy for amblyopia in infants and young children improves visual acuity and may improve strabismus in some children. Although pleoptics and other eye exercises or forms of vision therapy are promoted for the treatment of amblyopia, there are insufficient clinic-based studies to make a recommendation for use of these techniques (AAO, 2007b).

**Binocular Vision Disorders (Strabismic and Nonstrabismic Conditions):** Normal binocular vision depends on motor alignment, coordination of the eyes, and sensory fusion (i.e., sensory integration of information from the two eyes). Symptoms of binocular eye problems include eyestrain, difficulty focusing, double vision, and headache. Disorders in this category involve difficulty in fusing or combining information from each eye to form one fused image. Binocular disorders include strabismic and nonstrabismic dysfunctions.

Strabismic vision disorders are characterized by the inward or outward deviation of one or both eyes, causing the two eyes to be directed to different points when viewing the same object. Strabismic conditions include esotropia (eye turns inward) and exotropia (i.e., eye turns outward). These conditions may be congenital or result from trauma or disease. Strabismus may result in diplopia, suppression of vision of one eye, amblyopia, impaired depth perception and an undesirable appearance. Strabismus is a common visual abnormality found in children. Adult-onset, acquired strabismus (e.g., due to trauma) is a misalignment that occurs after normal binocular vision has developed. It may be too late for adults with untreated congenital strabismus to treat the associated amblyopia and depth perception impairment; therefore, the goal of adult treatment is often purely cosmetic. Treatment for acquired or congenital strabismus in children is usually aimed at restoring the ability to maintain single binocular vision and fusion of images and at improving impaired depth perception. Interventions for treating strabismus include surgery to the extraocular muscles and optical manipulations with corrective glasses, as well as miotic and mydriatic medications and botulinum toxin. Vision therapy modalities have been proposed as treatments for strabismic conditions.

In nonstrabismic disorders, the eyes tend to turn, although this tendency is controlled at times. Nonstrabismic binocular dysfunctions include convergence insufficiency, convergence excess, divergence insufficiency, and divergence excess. The major consequence of any nonstrabismic anomaly of binocular vision is asthenopia, the subjective symptoms of ocular fatigue that include eyestrain, discomfort and headaches arising from use of the eyes.

**Literature Review – Strabismic Conditions:** Evidence evaluating the effectiveness of vision therapy for strabismic disorders exists primarily in the form of case studies and case series with few RCTs (Scheiman, et al., 2005). Limitations to the reported evidence include varied treatment approaches, small sample sizes, lack of control groups, lack of randomization, limited follow-up, patient selection bias, and lack of standardization of treatment and outcome measures. One large, multicenter clinical RCT (n=286) supported by the National Eye Institute (NEI) yielded evidence to suggest that the use of prism adaptation is appropriate prior to surgery as a treatment for acquired esotropia. The Prism Adaptation Study (PAS) defined prism adaptation as the preoperative wearing of Fresnel prisms to offset the angle of esotropia, with adjustment of prism power over time to accommodate buildup to larger angles of esotropia until fusion is achieved or until it has been demonstrated that fusion cannot be attained (NEI, 1999).

**Literature Review – Nonstrabismic Conditions:** Convergence insufficiency is the most evaluated of the nonstrabismic disorders and has been studied in RCTs and case series (Scheiman, et al., 2010; Aziz, et al., 2007; Scheiman, et al., 2005b). The Convergence Insufficiency Treatment Trial (CITT) Study Group conducted a multicenter randomized clinical trial (n=221) which compared home-based protocols to office-based treatments for symptomatic convergence insufficiency. At 12 weeks of follow-up, the office-based treatment was reported to result in a significantly greater improvement in symptoms and clinical measures of near point of convergence and positive fusional vergence compared to the other protocols (CITT Study Group, 2008). One year post-treatment, the participants (n=79) who were asymptomatic after a 12-week program of office-based treatment for convergence insufficiency maintained their improvements (CITT Study Group, 2009).

Insufficient evidence exists in the published, peer-reviewed literature to conclude that vision therapy is effective for the treatment of any of the strabismic disorders except preoperative prism adaptation for acquired esotropia.

Limited evidence in the medical literature and professional society guidance support the use of orthoptic therapy for the treatment of convergence insufficiency. The role of vision therapy in managing other nonstrabismic

binocular disorders has not been established. Available evidence exists primarily in the form of uncontrolled or poorly controlled studies with significant methodological flaws. Limitations of the available data include lack of long-term data, patient selection bias, failure to use controls, and retrospective design.

**Professional Societies/Organizations:** The AAO Preferred Practice Pattern for the management of esotropia and exotropia states that orthoptic therapy may improve fusional control in patients with intermittent exotropia. Patients with the convergence insufficiency type of exotropia (exotropia greater at near) and symptoms at near viewing (typically reading) may be good candidates for orthoptic therapy. Near point of convergence exercises on an accommodative target are recommended if the near point of convergence is distant. Convergence exercises with a prism can be beneficial once the near point of convergence improves (AAO, 2007a).

**Myopia, Hyperopia and Astigmatism:** The AAO, in a complementary therapy assessment of visual training for refractive errors, found no evidence that visual training has any effect on the progression of myopia or that it results in the improvement of visual function for patients with hyperopia or astigmatism (AAO, 2004).

### **Learning Disabilities**

The use of vision therapy techniques to treat learning disabilities stems from the association between vision and learning, i.e., the role of oculomotor skills and visual perception in learning skills such as reading and writing. Vision therapy practitioners identify three interrelated areas of visual function which they suggest should be evaluated to identify learning-related visual problems (AAO, 2007):

- visual pathway integrity, including eye health, visual acuity and refractive status
- visual efficiency, including accommodation (focusing), binocular vision (eye teaming) and eye movements
- visual information processing, including identification and discrimination, spatial awareness, and integration with other senses

**Literature Review:** A systematic review by Rawstron et al. (2005) analyzed the evidence evaluating the efficacy of eye exercises. It was found that small controlled trials and a large number of cases support the treatment of convergence insufficiency. Less robust evidence was found to indicate that visual training may be useful in developing fine stereoscopic skills and improving visual field remnants after brain damage. It was stated that there is no clear evidence in the published literature to support the use of eye exercises in a wide range of conditions including vergence problems, ocular motility disorders, accommodative dysfunction, amblyopia, learning disabilities, dyslexia, asthenopia, myopia, stereopsis, visual field defects and visual acuity. Therefore, the use of eye exercises in the treatment of these conditions remains controversial (Rawstron, et al., 2005).

An ICSI (Institute for Clinical Systems Improvement) technology assessment found vision therapy to be safe when preceded by a comprehensive eye examination that rules out a serious condition requiring medical or surgical intervention. According to the ICSI committee, a review of available studies provided inadequate scientific evidence to allow for a conclusion to be drawn about the efficacy of vision therapy for patients with learning disabilities, amblyopia, strabismus, convergence insufficiency or accommodative disorders (ICSI, 2003).

There is a lack of consistent evidence in the published, peer-reviewed, scientific literature to support vision therapy, in the form of either orthoptic vision therapy or behavioral vision therapy, or through the use of colored overlays or lenses, for the treatment of any type of learning or reading disability. The available evidence does not support the conclusion that vision therapy improves reading comprehension.

**Professional Societies/Organizations:** According to the AAO, currently there is no adequate scientific evidence to support the view that subtle eye or visual problems cause learning disabilities. The evidence does not support the concept that vision therapy or tinted lenses or filters are effective, directly or indirectly, in the treatment of learning disabilities. Therefore the claim that vision therapy improves visual efficiency cannot be substantiated. Treatment approaches that lack scientific evidence of efficacy, including eye exercises, behavioral vision therapy, or special tinted filters or lenses, are not endorsed and should not be recommended (AAO, 2009).

### **Summary**

Insufficient evidence exists in the published, peer-reviewed, scientific literature to support the use of vision therapy, visual training, vision training, behavioral vision therapy or orthoptics for any of the following conditions:

- accommodative disorders, including accommodative spasm or excess, accommodative infacility, accommodative insufficiency and ill-sustained accommodation
- amblyopia (except for occlusion therapy, as previously noted)
- strabismic binocular disorders, including esotropia (except for preoperative prism adaptation for acquired esotropia, as noted above), exotropia and hypertropia
- nonstrabismic binocular disorders, such as convergence excess, divergence insufficiency and divergence excess (except for convergence insufficiency as previously noted)
- learning disabilities, including, but not limited to, reading disabilities, attention-deficit/hyperactivity disorder, and dyslexia
- myopia, hyperopia, presbyopia and astigmatism
- ocular motility disorders, eye movement disorders, and oculomotor dysfunctions
- visual information processing disorders, including visual-motor integration and integration with other sensory modalities

---

## Coding/Billing Information

**Note:** This list of codes may not be all-inclusive.

### Experimental/Investigational/Unproven/Not Covered:

CPT* Codes	Description
92065	Orthoptic and/or pleoptic training with continuing medical direction and evaluation

ICD-9-CM Diagnosis Codes	Description
	All codes

\*Current Procedural Terminology (CPT®) ©2010 American Medical Association: Chicago, IL.

---

## References

1. American Academy of Ophthalmology. Alternative Therapies. Vision Therapies for Learning Disabilities. 2007 May. Accessed Oct 11, 2010. Available at URL address: <http://www.aao.org/eyecare/treatment/alternative-therapies/vision-therapies-learning-disabilities.cfm>
2. American Academy of Ophthalmology. Complementary therapy assessment. Visual training for refractive errors. American Academy of Ophthalmology Complementary Therapy Task Force. 2004 Oct. Accessed Oct 11, 2008. Available at URL address: [http://www.aao.org/aao/education/library/cta/upload/visual\\_training\\_2004.pdf](http://www.aao.org/aao/education/library/cta/upload/visual_training_2004.pdf)
1. American Academy of Ophthalmology. Preferred Practice Pattern®. Amblyopia. 2007b Sep. Accessed Oct 10, 2008. Available at URL address: <http://one.aao.org/asset.axd?id=990d3861-25e9-4bc9-ad7e-9796b932a4d9>
2. American Academy of Ophthalmology. Preferred Practice Pattern®. Esotropia and Exotropia. 2007a Sep. Accessed Oct 11, 2010. Available at URL address: <http://one.aao.org/asset.axd?id=283e0e2d-0012-4a9d-88f4-0835a70adafc>

3. American Academy of Ophthalmology. Policy statement. Learning Disabilities, Dyslexia and Vision. A joint statement of the American Academy of Pediatrics (Section on Ophthalmology, Council on Children with Disabilities), the American Academy of Ophthalmology, the American Association for Pediatric Ophthalmology and Strabismus and the American Association of Certified Orthoptists. 2009. accessed Oct 11, 2010. Available at URL address:  
<http://one.aao.org/CE/PracticeGuidelines/ClinicalStatements.aspx>
4. American Academy of Optometry. Vision therapy. A joint organizational policy statement of the American Academy of Optometry and the American Optometric Association. June, 1999. Accessed Oct 11, 2010. Available at URL address: <http://www.aaopt.org/about/position/index.asp>
5. American Academy of Pediatrics. Policy statement. Learning disabilities, dyslexia, and vision: a subject review. *Pediatrics*. 1998 Nov;102(5):1217-9. Accessed Oct 11, 2010. Available at URL address:  
<http://www.aap.org/policy/re9825.html>
6. Aziz S, Cleary M, Stewart HK, Weir CR. Are orthoptic exercises an effective treatment for convergence and fusion deficiencies? *Strabismus*. 2006 Dec;14(4):183-9.
7. Ciuffreda KJ. The scientific basis for and efficacy of optometric vision therapy in nonstrabismic accommodative and vergence disorders. *Optometry*. 2002 Dec;73(12):735-62.
8. Convergence Insufficiency Treatment Trial Study Group. Randomized clinical trial of treatments for symptomatic convergence insufficiency in children. *Arch Ophthalmol*. 2008 Oct;126(10):1336-49.
9. Convergence Insufficiency Treatment Trial Study Group. Long-term effectiveness of treatments for symptomatic convergence insufficiency in children. *Optom Vis Sci*. 2009 Sep;86(9):1096-103.
10. EyeCare America<sup>®</sup>, Foundation of the American Academy of Ophthalmology (AAO). Vision Therapies for Learning Disabilities. Reviewed May 2007. Accessed Oct 11, 2007. Available at URL address:  
<http://www.eyecareamerica.org/eyecare/treatment/alternative-therapies/vision-therapies-learning-disabilities.cfm>
11. Institute for Clinical Systems Improvement (ICSI). Technology assessment report. Vision therapy. 2003 Jan. Accessed Oct 4, 2004. Available at URL address:  
<http://www.icsi.org/knowledge/detail.asp?catID=107&itemID=753>
12. National Eye Institute (NEI). Amblyopia treatment study: occlusion versus pharmacologic therapy for moderate amblyopia. Press release announcing results. Clinical studies supported by the National Eye Institute. Updated 2002 Mar 13. Accessed Oct 11, 2010. Available at URL address:  
<http://www.nei.nih.gov/neitrials/static/study73.htm>
13. National Eye Institute (NEI). NEI Clinical Studies. Prism Adaptation Study (PAS), The. 1999 Sep 23. Accessed Oct. 11, 2010. Available at URL address:  
<http://www.nei.nih.gov/neitrials/static/study20.asp#background>
14. National Eye Institute (NEI). Report of the Strabismus, Amblyopia, and Visual Processing Panel. Vision-Research-A National Plan: 1999-2003. Accessed Oct 11, 2010. Available at URL address:  
[http://www.nei.nih.gov/resources/strategicplans/neiplan/frm\\_strabismus.asp](http://www.nei.nih.gov/resources/strategicplans/neiplan/frm_strabismus.asp)
15. Pediatric Eye Disease Investigator Group, The. A randomized trial of atropine vs. patching for treatment of moderate amblyopia in children. *Arch Ophthalmol*. 2002 Mar;120(3):268-78.
16. Pediatric Eye Disease Investigator Group, Repka MX, Kraker RT, Beck RW, Holmes JM, Cotter SA, et al. A randomized trial of atropine vs patching for treatment of moderate amblyopia: follow-up at age 10 years. *Arch Ophthalmol*. 2008 Aug;126(8):1039-44.
17. Rawstron JA, Burley CD, Elder MJ. A systematic review of the applicability and efficacy of eye exercises. *J Pediatr Ophthalmol Strabismus*. 2005 Mar-Apr;42(2):82-8.

18. Scheiman M, Cotter S, Rouse M, Mitchell GL, Kulp M, Cooper J, et al. Randomised clinical trial of the effectiveness of base-in prism reading glasses versus placebo reading glasses for symptomatic convergence insufficiency in children. Br J Ophthalmol. 2005a Oct;89(10):1318-23.
19. Scheiman M, Mitchell GL, Cotter S, Kulp M, Cooper J, Rouse M, et al. A randomized clinical trial of vision therapy/orthoptics versus pencil pushups for the treatment of convergence insufficiency in young adults. Optom Vis Sci. 2005b Jul;82(7):583-95.
20. Scheiman M, Kulp MT, Cotter S, Mitchell GL, Gallaway M, Boas M, Coulter R, Hopkins K, Tamkins S; Convergence Insufficiency Treatment Trial Study Group. Optom Vis Sci. 2010 Aug;87(8):593-603.
21. Shotton K, Elliott S. Interventions for strabismic amblyopia. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006461.

## Policy History

<b>Pre-Merger Organizations</b>	<b>Last Review Date</b>	<b>Policy Number</b>	<b>Title</b>
CIGNA HealthCare	11/15/2008	0221	Vision Therapy/Orthoptics

“CIGNA”, “CIGNA HealthCare” and the “Tree of Life” logo are registered service marks of CIGNA Intellectual Property, Inc., licensed for use by CIGNA Corporation and its operating subsidiaries. All products and services are provided by such operating subsidiaries and not by CIGNA Corporation. Such operating subsidiaries include Connecticut General Life Insurance Company, CIGNA Health and Life Insurance Company, CIGNA Behavioral Health, Inc., CIGNA Health Management, Inc., and HMO or service company subsidiaries of CIGNA Health Corporation and CIGNA Dental Health, Inc. In Arizona, HMO plans are offered by CIGNA HealthCare of Arizona, Inc. In California, HMO plans are offered by CIGNA HealthCare of California, Inc. In Connecticut, HMO plans are offered by CIGNA HealthCare of Connecticut, Inc. In North Carolina, HMO plans are offered by CIGNA HealthCare of North Carolina, Inc. In Virginia, HMO plans are offered by CIGNA HealthCare Mid-Atlantic, Inc. All other medical plans in these states are insured or administered by Connecticut General Life Insurance Company or CIGNA Health and Life Insurance Company.